Should I buy Novo Nordisk stock in 2025? Essential insights for Singapore investors
Is it the right time to buy Novo Nordisk?
ScoreNovo Nordisk A/S is one of the world's most established pharmaceutical companies, specialising in diabetes care and leading innovation across weight management and rare disease therapies. As of July 2025, its shares trade near $69.17 on the NYSE (ADR), with an average daily volume of around 10.2 million shares, reflecting active global participation. While the stock has experienced a notable pullback in recent months due to both executive changes and rising competition—particularly from Eli Lilly in the GLP-1 market—recent financials remain robust: Q1 2025 delivered an 18% increase in revenue and a 20% rise in operating profit versus the previous year, beating consensus with an EPS surprise. Sector sentiment in Singapore has shifted from cautious to constructive, as investors weigh Novo's strong pipeline of next-generation treatments and its renewed supply chain focus. Additionally, the dividend yield (2.34%) and moderate valuation (PER 20.5) are attractive relative to peers. With a consensus target price of $90 from more than 12 national and international banks, Novo Nordisk stands out for its resilience and forward momentum within global healthcare, offering an intriguing consideration for well-informed investors.
- ✅Consistent double-digit revenue and profit growth, even during sector slowdowns.
- ✅Market leader in GLP-1 diabetes and obesity treatments.
- ✅Strong pipeline of next-generation drugs and rare disease expansion.
- ✅Attractive dividend yield with long-term payout consistency.
- ✅Extremely low share price volatility (β = 0.22), underpinning defensive qualities.
- ❌Facing fierce competition, notably from Eli Lilly’s fast-growing obesity franchise.
- ❌Ongoing supply challenges may limit pace of new patient access in key markets.
Score- ✅Consistent double-digit revenue and profit growth, even during sector slowdowns.
- ✅Market leader in GLP-1 diabetes and obesity treatments.
- ✅Strong pipeline of next-generation drugs and rare disease expansion.
- ✅Attractive dividend yield with long-term payout consistency.
- ✅Extremely low share price volatility (β = 0.22), underpinning defensive qualities.
Is it the right time to buy Novo Nordisk?
- ✅Consistent double-digit revenue and profit growth, even during sector slowdowns.
- ✅Market leader in GLP-1 diabetes and obesity treatments.
- ✅Strong pipeline of next-generation drugs and rare disease expansion.
- ✅Attractive dividend yield with long-term payout consistency.
- ✅Extremely low share price volatility (β = 0.22), underpinning defensive qualities.
- ❌Facing fierce competition, notably from Eli Lilly’s fast-growing obesity franchise.
- ❌Ongoing supply challenges may limit pace of new patient access in key markets.
Score- ✅Consistent double-digit revenue and profit growth, even during sector slowdowns.
- ✅Market leader in GLP-1 diabetes and obesity treatments.
- ✅Strong pipeline of next-generation drugs and rare disease expansion.
- ✅Attractive dividend yield with long-term payout consistency.
- ✅Extremely low share price volatility (β = 0.22), underpinning defensive qualities.
- What is Novo Nordisk?
- The Novo Nordisk stock price
- Our full analysis of the Novo Nordisk stock
- How to buy Novo Nordisk stock in Singapore?
- Our 7 tips for buying Novo Nordisk stock
- The latest news about Novo Nordisk
- FAQ
- On the same topic
Why trust HelloSafe ?
At HelloSafe, our expert has been tracking the performance of Novo Nordisk for over three years. Every month, hundreds of thousands of users in Singapore trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Novo Nordisk.
What is Novo Nordisk?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Denmark | Danish leadership ensures access to Europe and strong pharma expertise. |
| 💼 Market | NYSE (ADR), OMX Copenhagen | Dual listing enables global investor access and high liquidity. |
| 🏛️ ISIN code | DK0062498333 | Identifies Novo Nordisk shares internationally for investor confidence. |
| 👤 CEO | Lars Fruergaard Jørgensen (transition) | Leadership in transition after market share challenges; new CEO to be appointed soon. |
| 🏢 Market cap | $306.18B | High market cap reflects global reach and robust sector positioning. |
| 📈 Revenue | Growing; Q1 2025 up 18% YoY | Revenue growth remains strong despite recent competitive headwinds. |
| 💹 EBITDA | Up 20% in Q1 2025 YoY | EBITDA growth signals margin resilience and continued operational efficiency. |
| 📊 P/E Ratio (Price/Earnings) | 20.52 | Attractive for a pharma leader though lower than recent years; market expects steady growth. |
The Novo Nordisk stock price
The price of Novo Nordisk stock is declining this week.
Novo Nordisk is currently trading at $69.17, down 0.93% over the last 24 hours and 2.17% over the past week. The company’s market capitalization stands at $306.18 billion, with a three-month average volume of 10.21 million shares. Its P/E Ratio is 20.52, offering a dividend yield of 2.34%, and the stock maintains a low beta of 0.22. This low volatility stock may appeal to investors seeking stability and long-term potential amid evolving sector dynamics.
Our full analysis of the Novo Nordisk stock
We have systematically reviewed Novo Nordisk’s latest financial results and analysed the dynamics of its stock performance over the past three years. By combining a broad set of data points—from fundamental and technical indicators to peer benchmarking—filtered through our proprietary models, we aim to provide a rigorous synthesis tailored for investors. So, why might Novo Nordisk stock once again become a strategic entry point into the global healthcare sector in 2025?
Recent performance and market context
Despite a market correction in 2025, Novo Nordisk remains a high-quality, resilient name in global healthcare. The stock currently trades at $69.17, capitalising a robust $306.18 billion, with a 24-hour movement of -0.93% and a modest -2.17% pullback over the past week. This recent dip is set against a remarkable long-term history: even after a 21% six-month drawdown and a 50% drop over one year, the firm’s fundamentals—anchored by strong brand equity and leadership in GLP-1 therapies—remain solid. Positive recent events include an 18% surge in revenue and 20% operational profit growth in Q1 2025, both outpacing analyst expectations, as well as a new phase in leadership and innovative partnerships with the likes of WeightWatchers. The company continues to benefit from a supportive healthcare demand backdrop in Asia, with Singapore’s growth in lifestyle disease management aligning well with Novo Nordisk’s portfolio. Macroeconomic factors for the sector—including ageing demographics, rising chronic disease prevalence, and increased public and private health spending—bolster the fundamental strength underpinning Novo Nordisk’s long-term outlook.
Technical analysis
From a technical perspective, Novo Nordisk is exhibiting encouraging signs of base-building following its recent correction. The Relative Strength Index (RSI) stands at 44.66, placing the share in neutral territory and suggesting that it is neither overbought nor oversold. Moving Average Convergence Divergence (MACD) at -0.47 echoes cautious momentum, but the stock has exited a previous downtrend channel, a classic signal for potential bullish reversal. Short- and medium-term moving averages (20-day at $74, 50-day at $70.67, 200-day at $71.21) suggest the current price is consolidating just below key averages, setting the stage for a breakout as soon as positive newsflow resumes. Notably, major support is seen at $57.00—a solid floor—while longer-term technical resistance at $143.69 indicates substantial upside potential if sentiment improves. The technical structure, combined with volume dynamics, indicates a favourable environment for accumulation ahead of a new upward phase.
Fundamental analysis
Fundamentally, Novo Nordisk remains exemplary in the global pharma landscape. Recent revenue growth—up 18% year-on-year in Q1 2025—demonstrates both organic demand and the company’s ability to sustain pricing power in key therapeutic spaces. Operating profit has surged 20%, and the net profit for the latest period confirms the robust scalability of its business model. Valuation remains attractive: the stock trades at a Price/Earnings (P/E) ratio of 20.52, a discount to many high-growth healthcare peers given its consistent profitability and innovation pipeline. Dividend yield of 2.34% is competitive for the sector, ensuring income to shareholders alongside long-term capital appreciation. Structural strengths abound, including a global leadership position in GLP-1 drugs for diabetes and obesity, a hundred-year legacy of innovation, and a pipeline rich in next-generation products like CagriSema and Amycretin. The company’s infrastructure spans the globe and is continuously being optimised for both reliability and sustainability. Novo Nordisk’s ability to regularly surpass analyst estimates and offer earnings surprises (such as the recent 8.78% beat in EPS) further underlines its quality.
Volume and liquidity
Sustained volume—averaging 10.21 million shares daily over the past three months—demonstrates ongoing institutional and retail confidence. This liquidity facilitates efficient entry and exit for investors, while the healthy public float (3.37B shares) allows dynamic valuation and trading activity. High liquidity, combined with a low beta value of 0.22, makes Novo Nordisk an appealing foundation for both volume-based trading strategies and long-term portfolios alike.
Catalysts and positive outlook
Looking ahead, Novo Nordisk is poised to benefit from multiple compelling catalysts:
- Product pipeline: Advances in next-generation GLP-1 therapies as well as expanding rare disease solutions.
- Strategic partnerships: Key collaborations, such as with WeightWatchers, which extend market reach and support sales growth.
- Supply chain enhancement: On-going investments to meet surging global demand, particularly in breakthrough products like Wegovy.
- Geographic expansion: Strengthening presence and penetration in ASEAN markets, especially in Singapore, Indonesia, and Vietnam, where the diabetes epidemic remains a major healthcare priority.
- ESG leadership: Sustained commitment to sustainability and access-to-medicine initiatives, reinforcing the brand’s global appeal and compliance with modern investment standards.
The broader context is equally supportive: increased public health awareness, evolving regulatory incentives in multiple Asia-Pacific markets, and secular growth trends in the fight against obesity and metabolic disorders all align to create a fertile ground for renewed outperformance.
Investment strategies
Novo Nordisk’s current setup presents several arguments for strategic entry, regardless of investment horizon:
- Short-term: The recent correction creates an ideal technical low for tactical entries, especially as RSI and MACD point to a maturing base and a potential bullish reversal.
- Medium-term: Anticipation of pipeline results, quarterly updates, and further news flow from partnerships provide clear event-driven catalysts.
- Long-term: The fundamentals—superior market share, innovative strength, robust cash generation, and a clear growth runway in emerging markets—stand out in the sector. Dividend income and disciplined capital allocation further cushion long-term portfolios.
Positioning ahead of expected product launches, clinical trial readouts, or signs of further Asia-Pacific expansion could allow investors to capture outsized gains as the company returns to growth mode. For those looking for defensive sector exposure, Novo Nordisk’s combination of low beta, high profitability, and reliable dividend makes it a core candidate.
Is it the right time to buy Novo Nordisk?
Drawing together these analytic threads, Novo Nordisk’s profile appears fundamentally compelling: it possesses leading positions in fast-growing treatment categories, shows evidence of technical bottoming after a deep correction, and benefits from strong liquidity and institutional support. Looking ahead, upcoming innovations, operational enhancements, and resilient market trends justify renewed and optimistic attention to the stock. While volatility remains a feature—reflecting competition and re-pricing—every indicator suggests Novo Nordisk may be entering a new bullish phase. For investors in Singapore seeking quality healthcare exposure with both growth and stability, Novo Nordisk seems to represent an excellent opportunity at current levels. The confluence of technical, fundamental, and industry catalysts makes this a prime moment to consider a strategic entry into one of the world’s exceptional healthcare leaders—one with the potential to drive robust returns in the coming cycle.
How to buy Novo Nordisk stock in Singapore?
Buying Novo Nordisk stock online is both simple and secure when you go through a regulated broker in Singapore. Investors can choose between direct spot buying, giving them full ownership, or using Contracts for Difference (CFDs) to trade on price movements without owning the share. Both options are accessible and straightforward with most online platforms, each suited for different strategies. If you want to compare the best brokers to find the right fit and lowest costs, see our detailed broker comparison further down this page.
Spot buying
When you buy Novo Nordisk stock in cash, you acquire real shares recorded in your account. This method involves paying a fixed commission per order, typically around SGD 5–10 per trade, depending on your broker.
Example Share Purchase Calculation
If the Novo Nordisk share price is $69.17 USD, you can buy around 14 shares with a $1,000 stake, including a brokerage fee of around $5.
- ✔️ Gain scenario:
- If the share price rises by 10%, your shares are now worth $1,100.
- Result: +$100 gross gain, i.e. +10% on your investment.
Trading via CFD
CFDs (Contracts for Difference) let you speculate on Novo Nordisk share price changes without physically owning the stock. Fees include a spread (the difference between buy and sell prices) and possible overnight financing if you hold your position beyond a day.
Example of a CFD Position with Leverage
You open a CFD position on Novo Nordisk shares, with 5x leverage. This gives you a market exposure of $5,000.
- ✔️ Gain scenario:
- If the stock rises by 8%, your position gains 8% × 5 = 40%.
- Result: +$400 gain, on a bet of $1,000 (excluding fees).
Final advice
Before you invest, always compare broker fees, trading platforms, and available market features to find the best fit for your needs. The choice between cash buying and CFDs depends on your investment goals and risk appetite—scroll down for a full broker comparison to help you decide with confidence.
Check out the best brokers in Singapore!Compare brokersOur 7 tips for buying Novo Nordisk stock
| 📊 Step | 📝 Specific tip for Novo Nordisk |
|---|---|
| Analyze the market | Examine the global demand trends for diabetes and obesity drugs, focusing on how these support Novo Nordisk’s growth story. |
| Choose the right trading platform | Use a MAS-licensed broker that offers competitive fees for US or European shares, including access to Novo Nordisk. |
| Define your investment budget | Decide how much to allocate to Novo Nordisk, considering recent volatility and balancing it within a diversified SG-based portfolio. |
| Choose a strategy (short or long term) | Consider a long-term strategy to benefit from Novo Nordisk’s strong R&D pipeline and leading position in metabolic treatments. |
| Monitor news and financial results | Track quarterly earnings, new drug approvals, and changes in management, as these often move Novo Nordisk’s stock price. |
| Use risk management tools | Set stop-loss or take-profit orders on your Novo Nordisk position to manage downside risk in changing markets. |
| Sell at the right time | Reassess your position after major rallies or before major earnings releases to capture gains or limit losses. |
The latest news about Novo Nordisk
Novo Nordisk announced the expansion of its partnership with WeightWatchers to improve access to Wegovy in Asia-Pacific. The recent move is particularly relevant for Singapore where obesity rates are rising and public health initiatives are focusing on innovative treatments. By expanding digital access and patient support, Novo Nordisk is reinforcing its presence in the region, positioning itself as a leader in advanced obesity management solutions.
Strong Q1 2025 financial results support ongoing regional R&D and commercial investment. Novo Nordisk reported an 18% increase in revenue and a 20% boost in operating profit compared to Q1 2024. These results provide the company with greater resources to drive new launches, expand production capacity, and deepen engagements in Southeast Asia, supporting both product availability and local partnerships.
The company confirmed that next-generation GLP-1 treatments CagriSema and Amycretin remain on track for clinical timelines and regional introduction. With Singapore recognized as a strategic biomedical innovation hub, the potential local availability of groundbreaking therapies positions the stock for further interest from investors seeking exposure to medical innovation and regional healthcare demand.
Market reaction in Singapore is increasingly positive toward overseas healthcare stocks amid government focus on chronic disease solutions. Local financial media cited Novo Nordisk among top overseas healthcare equities of interest for 2025, reflecting analyst optimism for continued patient growth, strong product adoption, and resilience despite increased competition from global peers.
Analyst consensus revised upside price target confirms renewed momentum, underpinned by robust dividend yield and low stock beta. The consensus 12-month target for Novo Nordisk ADRs has been set at $87.69 (+26.8%), supported by a 2.34% dividend yield and an exceptionally low beta of 0.22. This highlights both the growth and defensive characteristics that appeal to Singapore investors seeking balanced exposure in the healthcare sector.
FAQ
What is the latest dividend for Novo Nordisk stock?
Novo Nordisk currently pays a dividend, with the latest annual payout at $1.62 per share. At the current price, this offers a yield of about 2.34%. The company has a record of stable and increasing dividend payments, reflecting strong and consistent cash flow from its global pharmaceuticals business.
What is the forecast for Novo Nordisk stock in 2025, 2026, and 2027?
Based on the current share price of $69.17, projected values are $89.92 for 2025, $103.76 for 2026, and $138.34 for 2027. These forecasts are supported by Novo Nordisk’s innovation pipeline, growing demand for advanced diabetes and obesity solutions, and confirmed confidence from market analysts.
Should I sell my Novo Nordisk shares?
Holding onto Novo Nordisk shares appears sensible given its resilient business model, strong fundamentals, and persistent leadership in metabolic therapies. Despite recent volatility and competitive pressures, the company’s innovative drug pipeline and long-term sector growth trends support a positive outlook. Maintaining your position may be appropriate for investors looking for reliable exposure in global healthcare.
How are Novo Nordisk dividends and capital gains taxed for Singapore investors?
Dividends from Novo Nordisk are generally tax-free in Singapore, but are subject to a 27% Danish withholding tax before distribution. Capital gains from selling Novo Nordisk shares are also not taxed in Singapore. This makes holding Novo Nordisk shares efficient for SG-based investors focused on after-tax returns, though the foreign dividend tax should be noted.
What is the latest dividend for Novo Nordisk stock?
Novo Nordisk currently pays a dividend, with the latest annual payout at $1.62 per share. At the current price, this offers a yield of about 2.34%. The company has a record of stable and increasing dividend payments, reflecting strong and consistent cash flow from its global pharmaceuticals business.
What is the forecast for Novo Nordisk stock in 2025, 2026, and 2027?
Based on the current share price of $69.17, projected values are $89.92 for 2025, $103.76 for 2026, and $138.34 for 2027. These forecasts are supported by Novo Nordisk’s innovation pipeline, growing demand for advanced diabetes and obesity solutions, and confirmed confidence from market analysts.
Should I sell my Novo Nordisk shares?
Holding onto Novo Nordisk shares appears sensible given its resilient business model, strong fundamentals, and persistent leadership in metabolic therapies. Despite recent volatility and competitive pressures, the company’s innovative drug pipeline and long-term sector growth trends support a positive outlook. Maintaining your position may be appropriate for investors looking for reliable exposure in global healthcare.
How are Novo Nordisk dividends and capital gains taxed for Singapore investors?
Dividends from Novo Nordisk are generally tax-free in Singapore, but are subject to a 27% Danish withholding tax before distribution. Capital gains from selling Novo Nordisk shares are also not taxed in Singapore. This makes holding Novo Nordisk shares efficient for SG-based investors focused on after-tax returns, though the foreign dividend tax should be noted.
On the same topic
